Document:

STEM CELL THERAPY INTERNATIONAL, INC.

                   SCTI BUSINESS DEVELOPMENT ADVISORY AGREEMENT

     THIS  AGREEMENT  is made this 1st day of January, 2006, by and between STEM
CELL THERAPY INTERNATIONAL, INC.; a corporation duly incorporated under the laws
of Nevada, with its principal office located at 2203 North Lois Ave., 9th Floor,
Tampa,  Florida  33594  ("the Company''), and ALEXANDER KULIK as a member of the
SCTI  Business  Development  Advisor,  herein  ("the  Business  Advisor").

     In  consideration  of the mutual agreements contained in this document, the
parties,  intending  to  be  legally  bound,  agree  as  follows:

 1.     INDEPENDENT  CONTRACTOR.

     The  Business Advisor will be an independent contractor and not an Employee
of  the  Company.

     The  Business  Advisor  will  not  be entitled to receive any compensation,
commissions  or  benefits other than those expressly provided in this Agreement.

2.     SCOPE  OF  DUTIES.

WHEREAS,  The  Business  Advisor  certifies  that  there  are  no  outstanding
agreements  or  obligations  that  conflict  with  any of the provisions of this
Agreement,  or that would preclude or in any way compromise the Business Advisor
in  compliance  with  the  provisions  hereof.

WHEREAS,  The  Company  has  engaged  the  Business Advisor to act as a business
consultant  and  advisor  in  connection  with  the  Company's business matters;

WHEREAS,  The  Business  Advisor has experience in providing business consulting
and  advisory  services to corporations, governmental agencies, partnerships and
other  business  organizations;

NOW  THEREFORE,  in  consideration of, and for the mutual promises and covenants
contained  herein, and for other good and valuable consideration, the receipt of
which  is  hereby  acknowledged,  the  parties  agree  as  follows:

         (1)  PURPOSE.  The  company  hereby  engages  the Business Advisor on a
non-exclusive  basis for the term specified in this Agreement to render business
consulting and advisory services upon the terms and conditions set forth herein.

         (2)  REPRESENTATIONS  OF  THE  BUSINESS  ADVISOR  AND  THE COMPANY. The
Business Advisor represents and warrants to the Company that it is free to enter
into  this  Agreement  and  the  business  consulting and advisory service to be
provided  pursuant  to  this  Agreement  are  not  in  conflict  with  any other
contractual  or  other  obligation  to  which the Business Advisor is bound. The
Company  acknowledges  that the Business Advisor is in the business of providing
business  consulting  and  advisory  services  to others and that nothing herein
contained  shall  be  construed  to  limit  or  restrict the Business Advisor in
conducting  such  business with respect to others, or rendering such services to
others.

         (3)  DUTIES OF THE BUSINESS ADVISOR. During the term of this Agreement,
the  Business  Advisor  will  provide  the  Company with business consulting and
advisory  services as specified below at the request of the Company from time to
time,  provided  that  the  Business  Advisor shall not be required to undertake
duties  not  reasonably  within  the scope of the services in which the Business
Advisor  is  engaged  generally.  In  performance  of these duties, the Business
Advisor  shall  provide  the  Company with the benefits of its best judgment and
efforts.  It  is  understood  and acknowledged by the parties that the amount of
time  spent  rendering  such  business consulting and advisory services shall be
determined  according  to  the  Business  Advisor's  and  the Company's mutually
convenient  schedule.

The  Business  Advisor's business consulting and advisory services shall include
but  are  not  limited  to:

              a)   Corporate structuring; set up and administer the UK office of
the  Company.

  b)   Interface  with  Governmental  agencies  to  provide  access to, and help
produce  to  documentation  to  obtain  research grants, secure funding sources,
participate  in patent filings, obtain special permits and address any licensing
issues.

   c)  Provide  business  liaison  with  London Stock Exchange and AIM market as
well  as  develop  affiliated  clinic's  and  treating  physicians in the target
countries  such  as  Switzerland,  Germany,  China,  Russia, Netherlands, Dubai,
Bahrain,  and any other countries the Advisor deems advantageous to the Company;
and

d)   Provide  general  business  planning, security, development and operations;
and

e)       Assist  with mergers and acquisitions, and other business combinations;
and

     f)   The  Business Advisor will be responsible to do the following as well:

(4)     The  Business  Advisor  agrees  to  participate  in conference calls and
meetings  with  the SCTI Corporate Officers and members of the Company's Medical
and  Scientific Business Advisory Board when his/her schedule allows, to discuss
the  latest technology in stem cell treatments and shall contribute with his/her
recommendations  on  future  progress  and  corporate  operations and direction.

(5)     The  Business  Advisor  will  be required to interact with SCTI treating
Physicians,  Medical and Scientific Advisory Board Members, Corporate Offers and
to  develop  strategic alliances with other corporations, governmental agencies,
research  organizations, universities and individuals outside of the Company for
the advancement of our knowledge and expertise in the treatment of patients with
our  various  stem  cell  Products.

(6)     The  Business  Advisor's roll will be to make sure that the Company will
maintain  its  competitive  edge  both  globally and in the United States in the
field  of stem cell treatments, research and the development of new technologies
and  vertical  markets.
(7)     The Business Advisor will assist in the Development of policies (per
country) and participate on the SCTI Bio-Ethics Committee.

3.     COMPENSATION.

     The  Company  shall  issue  ten thousand (10,000) shares of Rule 144 common
stock of the Company to the Business Advisor as compensation for the initial one
year  term  of  this  agreement,  as  follows:

     (a)     Thirty  days  after  the  execution  of this agreement, the Company
shall  issue  five  thousand  (5,000) shares of common stock under rule 144, and

     (b)     Six months after the execution of this agreement, the Company shall
issue  the  remaining  five thousand (5,000) shares common stock under rule 144.

     (c)     Compensation  for  successive renewal years under the terms of this
Agreement  shall  be  issued  at thirty days and six months after renewal in two
increments  of  five  thousand  shares  of  rule  144  common  stock.

4.     TERM.

This  Agreement will become effective on the date of execution and will continue
in  full  force  and  effect for a minimum period of one (1) year and thereafter
from year to year unless and until terminated by a party in accordance with this
Agreement.

5.     TERMINATION.

During  the  minimum  period  of  one  (1)  year,  either  party may immediately
terminate  this  Agreement  for  cause,  upon  written  notice for any breach of
contract,  if  the other party does not cure a material breach of this Agreement
within  thirty  (30)  days  of  receipt of written notice detailing such breach.

After  the  expiration  of  one  (1)  year  from  the  date of execution of this
agreement,  either  party  may  terminate  this  Agreement without cause and for
convenience with fourteen (14) days prior written notice to the other party.  At
any time, the parties may mutually agree in writing to terminate this Agreement.

6.     CONFIDENTIALITY.
          The  Business  Advisor  shall not use or divulge or communicate to any
person  (other  than those whose province it is to know the same or as permitted
or  contemplated  by  this  Agreement  or with the written approval of the other
party  or  as  may  be  required  by  law):
(i)                 any  Confidential  Company  Information;  or
(ii)                any  of  the  terms  of  this  Agreement

     The  Business  Advisor  shall  prevent  the  unauthorized  publication  or
disclosure  of  any such information, materials or documents and ensure that any
person  to  whom  the information, materials or documents are disclosed is aware
that  the  same  is  confidential  and  is covered by a similar duty to maintain
confidentiality.
     The  Business  Advisor shall ensure that any employees, consultants, agents
or  Business  Advisors  are  aware  of  and  comply with the confidentiality and
non-disclosure  provisions  contained  in  this  Section and shall indemnify the
Company  against  any loss or damage which the Company may sustain or incur as a
result  of  any  breach  of  the  terms  hereof  by the Business Advisor, or any
employees,  consultants,  agents  or  Business  Advisors.

CONFIDENTIAL  INFORMATION.

     The Business Advisor shall not directly or indirectly, communicate,
disclose or divulge to any person or entity, or use for their own benefit or the
benefit of any person or entity, any knowledge or information which the Business
Advisor may have acquired, no matter from whom or on what matter such knowledge
or information may have been acquired from the Company.
<PAGE>
These  provisions shall survive the expiration or termination of this Agreement.

7.     COVENANT  NOT  TO  COMPETE.

     The  Business Advisor, during the Term hereof, and for an additional period
of  two  years  thereafter  (the  ``Non-competition  Term''),  may  not:

(a)     Engage  or  participate  in  or  become  employed by, or render Business
Advisory  or  other  services  to,  any  business  entity that competes with the
Company  in  the  Ukraine  or  the  Dominican  Republic.

     If  the  foregoing  provision  is determined to be invalid by reason of the
length  of  any  period  or the size of the area set forth, such period of time,
such  area  or both will be considered to be reduced to a period of time or area
that  will  cure  such  invalidity.

(b)     Directly  or  indirectly  solicit  or induce any person, corporation, or
other  entity  that is a customer of the Company at the time of the execution of
this  agreement  or  that  was a customer at any time within the one-year period
immediately preceding such termination to become a customer of any other person,
corporation,  or  other  entity  competing  with  the Company or its Parent. The
Business  Advisor  further  agrees  that  he  or  she will not approach any such
person,  corporation,  or  other  entity  for  such  purposes.

(c)     Directly  or  indirectly solicit or induce any person who is an Employee
of  the  Company  or  its  Parent  to  become  employed  by  any person, firm or
corporation  competing  with the Company or its Parent, or approach any Employee
for  such  purpose.

(d)     Disclose  any  proprietary or confidential information of the Company or
its Parent relating to (i) the customers, clients, employees and accounts of the
Company  or  its  Parent,  including  but  not  limited  to  the identity of the
Company's  or  its  Parent's  customers  if  such  identity  is  proprietary  or
confidential;  (ii)  the  Company's  or  its Parent's business methods, systems,
plans,  policies,  and personnel; or (iii) the technical data, trade secrets, or
know-how  of the Company or its Parent, including, but not limited to, research,
product  plans, products, services, markets, software, developments, inventions,
processes,  formulas,  technology,  designs,  drawings,  engineering,  hardware,
configuration  information,  marketing,  finances  or other business information
disclosed  by  the Company or its Parent, either directly or indirectly, whether
in  writing,  orally  or  by  drawings  or  inspection  of  parts  or equipment.

8.     ARBITRATION  OF  DISPUTES.

(a)     The  Company  and  the  Business  Advisor  agree  that  any  dispute  or
controversy  arising  out  of  or  relating to any interpretation, construction,
performance  or  breach  of this Agreement, will be settled by arbitration to be
held  in Philadelphia County, Pennsylvania, in accordance with the rules then in
effect  of  the  American  Arbitration  Association.  The  arbitrator  may grant
injunctions  or  other  relief  in  the  dispute  or  controversy.

(b)     The  decision of the arbitrator will be final, conclusive and binding on
the  parties  to  the  arbitration.  Judgment may be entered on the arbitrator's
decision  in  any  court of competent jurisdiction. The Company and The Business
Advisor  will  each pay one-half of the cost and expenses of the arbitration and
each  will  separately  pay  its  respective  counsel  fees  and  expenses.

     The  Business  Advisor acknowledges that the services to be rendered by the
Business  Advisor  are  of a special, unique and extraordinary character, and in
connection  with  such  services,  the  Business  Advisor  will  have  access to
confidential  information  vital  to the Company's and its Parent's business. By
reason  of  this,  the  Business  Advisor  agrees  that  if the Business Advisor
violates  any  of  the  provisions  of  this  Agreement  with  respect  to
non-competition,  diversion  of  the  Company's  and  its  Parent's  clients  or
employees,  or  confidentiality,  the  Company  and  the  Parent  would  sustain
irreparable  harm,  and  therefore,  in  addition to any other remedies that the
Company and Parent may have under this Agreement, the Company and Parent will be
entitled  to  apply to any court of competent jurisdiction for equitable relief,
including  specific performance and injunctions restraining the Business Advisor
from  committing  or  continuing  any  such  violation  of  this  Agreement.

(b)     The  Business Advisor further agrees that no bond or other security will
be  required  in  obtaining  equitable  relief  and  the Business Advisor hereby
consents  to  the  issuance  of  an  injunction  and to the ordering of specific
performance.

(c)     The  Business Advisor further agrees that he will be required to sign an
INFORMATION & PRODUCT EVALUATION AND NON-DISCLOSURE AGREEMENT in order to accept
the  position  on  the  SCTI  Business  Advisory  Board.

9.     INDEMNITY

     The  Business  Advisor  shall  and  does hereby agree to defend, indemnify,
release,  and  save  harmless the Company, or companies agents, representatives,
servants,  employees, attorneys, and assigns from and against any and all suits,
actions,  judgments,  damages,  costs,  expenses, and attorneys fees incurred in
defense  of  any  action  or  proceeding  arising out of the performance of this
agreement

 10.     NOTICES.

     Any notice, request, demand or other communication required or permitted to
be  given under this Agreement will be sufficient if in writing and if delivered
personally, or sent by certified or registered mail as follows (or to such other
addressee or address as will be set forth in a notice given in the same manner):

If  to  the  Business  Advisor:

Alexander  Kulik

____________________________________

and
____________________________________

If  to  the  Company:

Calvin  C.  Cao
CEO/Chairman
Stem  Cell  Therapy  International  Inc.
2203  North  Lois  Avenue,  9th  Floor,  Suite  #901
Tampa,  FL  33607

     Any  such notice will be deemed to be given on the date delivered or mailed
in  the  manner  provided  above.

 11.     WAIVER  OF  BREACH.

     The  waiver  by  the  Company or by the Business Advisor of a breach of any
provision  of  this  Agreement  by  the  other  party  will  not  operate, or be
construed,  as  a  waiver  of  any  other  breach  of  such  other  party.

12.     ASSIGNMENT.

     This  Agreement  will  inure  to  the  benefit of, and be binding upon, the
Company,  its  successors  and  assigns.  This  Agreement will be binding on the
Business Advisor, the Business Advisor's heirs, executors or administrators, and
legal  representatives.  However,  this  Agreement will not be assignable by the
Business  Advisor  nor may the obligations of the Business Advisor be delegated,
without  express  written  consent  of  the  Company.

 13.     ENTIRE  AGREEMENT.

     This  Agreement  represents  the  entire  understanding  of the parties and
supersedes all previous agreements, oral or written, between the parties and any
modification  of  the  agreement must be in writing and executed by the parties.
This is a personal services contract and the Business Advisor may not assign any
rights  or  delegate  any  duties  of the Business Advisor under this agreement.

 14.     APPLICABLE  LAW.

     The  parties  agree  that  this  Agreement  will  be construed and enforced
pursuant  to  the  laws  of  the  Commonwealth  of  Pennsylvania.

     IN WITNESS WHEREOF, the parties have set their hands as of the day and year
first  above  written.

Stem Cell Therapy International, Inc.                       SCTI Business
Development Advisor

By:                              BY:  _______________________
Calvin  C.  Cao,  CEO/Chairman               Alexander  KulikJanuary 31, 2006

Mr. John P. O'Shea
President and CEO
WESTMINSTER SECURITIES CORPORATION
100 Wall Street
7th Floor
New York, NY 10005

     REF:  TERMINATION AND MODIFICATION OF ENGAGEMENT LETTER

Dear Mr. O'Shea:

This Termination and Modification Agreement ("Termination Agreement") modifies,
amends and terminates that certain Engagement Letter dated May 4, 2005
("Engagement Letter") pursuant to which Stem Cell Therapy International Corp.
("SCTI") agreed to engage Westminster Securities Corporation ("Westminster") in
connection with certain investment banking and financial advisory services.

Each of SCTI and Westminster acknowledge and agree that they desire to terminate
the precise terms of the Engagement Letter, but continue to work towards the
mutual benefit of each other in a potential long-term financial relationship.
Each of SCTI and Westminster acknowledge and agree that certain of the services
and activities referenced in the Engagement Letter have been completed by
Westminster and certain of the consideration payable thereunder has been paid.

Upon execution of this Termination Agreement and delivery of the consideration
set forth herein, the Engagement Letter be and hereby is terminated in its
entirety between SCTI and Westminster other than as specifically set forth
herein. Except as otherwise set forth herein, neither SCTI nor Westminster shall
have any further obligation one to the other as a consequence of the terms of
the Engagement Letter, including without limitation any obligation for a monthly
retainer.

In consideration of the termination of the Engagement Letter, SCTI agrees to
issue and deliver to Westminster a total of 120,000 shares (the "Shares") of
common stock of SCTI. Such Shares shall be issued and delivered to Westminster
within ten (10) business days of the date of execution of this Termination
Agreement. Westminster acknowledges and agrees that such Shares shall be
restricted securities, and that it is acquiring such Shares for its own account
(or the account of Westminster's employees who have rendered such services), has
no present intention of re-selling or distributing any of such Shares and has no
arrangement or understanding with any other persons regarding the sale or
distribution of such Shares. Westminster is acquiring the Shares in the ordinary
course of its business. Westminster represents and warrants that at the time of
acquisition of the Shares provided for herein, it is an "accredited investor" as
defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(7) or (a)(8) under the Securities
Act of 1933, as amended ("Securities Act"). Such Shares shall have piggyback
registration rights as follows:

If at any time or from time to time SCTI shall, within one year following
issuance of each certificate of Shares or common shares in Westminster's
possession prior to the date hereof, propose to file on its behalf or on behalf
of any of its security holders a registration statement under the Securities Act
on Form SB-2, S-1, S-2 or S-3 (or on any other form for the general registration
of securities) with respect to any class of securities (other than a Shelf
Registration Statement filed pursuant to Section 3 or a Registration Statement
on Form S-8), SCTI shall: (1) promptly give written notice to Westminster at
least ten days before the anticipated filing date, indicating the proposed
offering price and describing the plan of distribution; and (2) include in such
registration (and any related qualification under blue sky or other state
securities laws or other compliance) all the Shares specified by Westminster
(the "Specified Shares") in a written request (the "Registration Request") made
within five days after receipt of such written notice from SCTI. Notwithstanding
the foregoing, if the managing underwriter(s) of such offering reasonably
advise(s) SCTI in writing that marketing considerations require a limitation on
the securities, other than the securities SCTI intends to sell, to be included
in any Registration Statement filed hereunder to a certain number of shares (the
"Available Securities"), then SCTI shall in such case be obligated to
Westminster only with respect to such number of Available Securities. In
addition to the foregoing, upon the registration of any Shares or common shares
in Westminster's possession, Westminster or any subsequent holder(s) of the
Shares may request to have the restrictive legend removed pursuant to Rule 144
or any other applicable exemption from registration under the Securities Act.
In the event of a request for the restrictive legend to be removed from any or
all of the Shares, whether pursuant to registration under the Securities Act or
an applicable exemption therefrom, SCTI shall take action to allow for such
removal within five (5) business days of presentation of appropriate
documentation from the holder of such Shares, including that SCTI shall direct
its counsel to prepare a legal opinion as may be needed (at no cost to holder)
and/or instruct its transfer agent to remove the restriction from its records
and present the holder with a new, unlegended certificate.

SCTI acknowledges and agrees that the obligation of SCTI to pay to Westminster a
cash fee of Fifty Thousand Dollars ($50,000) required by Section 5 of the
Engagement Letter is in force and effect as a result of the introduction of a
Public Shell (as defined in the Engagement Letter) by Westminster. Westminster
acknowledges and agrees that Ten Thousand Dollars ($10,000) of such fee has been
paid. Westminster and SCTI agree that the balance of the fee (a total of Forty
Thousand Dollars ($40,000)) shall be paid by SCTI to Westminster in the event
SCTI receives aggregate gross proceeds of at least One Million Dollars
($1,000,000) in funding in one or more transactions, notwithstanding the source
of such funding.

In the event that Westminster presents to SCTI equity or debt funding which is
accepted by SCTI, SCTI agrees to pay to Westminster the Contingent Cash Fee and
the Contingent Warrant Fee set forth in Sections 3 and 4 of the Engagement
Letter.

Effective upon execution of this Termination Agreement, each of SCTI and
Westminster agrees to waive any and all causes of action or claims each may have
arising out of or related to the Engagement Letter or any other relationship
between the parties other than this Termination Agreement, and to release the
other, its affiliates, divisions, predecessors, successors and assigns, and each
and all of its present and former agents, officers, directors, attorneys, and
employees, from and against any and all claims, agreements, contracts,
covenants, representations, obligations, losses, liabilities, demands and causes
of action which Assignor may now or hereafter have or claim to have against
Assignee arising out of the Engagement Letter or any other relationship between
the parties other than this Termination Agreement. This Termination Agreement
may not be amended, canceled, revoked or otherwise modified except by written
agreement signed by all of the Parties.

This Termination Agreement shall be binding upon and shall inure to the benefit
of the Parties hereto and their respective partners, employees, agents,
servants, heirs, administrators, executors, successors, representatives and
assigns.

This Agreement will be governed by and construed in accordance with the laws of
the State of New York, without giving effect to its conflict of laws principles
or rules.  If a dispute or claim shall arise with respect to any of the terms or
provisions of this Agreement, or with respect to the performance by any of the
parties under this Agreement, then the parties agree to submit the dispute to
binding arbitration in a venue located in New York, NY in accordance with the
rules of the American Arbitration Association ("AAA").  The prevailing party
shall be reimbursed by the nonprevailing party for all reasonable attorney's
fees and costs (including all arbitration costs) incurred by the prevailing
party in resolving such dispute a

This Termination Agreement together with any of the terms of the Engagement
Letter retained by this Termination Agreement sets forth the entire agreement
and understanding of the Parties hereto and supersedes any and all prior
agreements, arrangements and understandings related to the subject matter
hereof. No understanding, promise, inducement, statement of intention,
representation, warranty, covenant or condition, written or oral, express or
implied, whether by statute or otherwise, has been made by any party hereto
which is not embodied in this Termination Agreement and no Party hereto shall be
bound by or liable for any alleged understanding, promise, inducement,
statement, representation, warranty, covenant or condition not so set forth.

If the foregoing accurately sets forth your understanding in this regard, please
date, sign and return the enclosed copy of this Termination Agreement.

This agreement may be executed in counterparts, each of which shall be deemed an
original  and all of which together will constitute one and the same instrument.

Yours very truly,

STEM CELL THERAPY INTERNATIONAL CORP.

By:______________________________________
Calvin Cao, President

STEM CELL THERAPY INTERNATIONAL INC.

By:______________________________________
Calvin Cao, President

Acknowledged and Accepted this
___ day of January, 2006

WESTMINSTER SECURITIES CORPORATION

By: _____________________________________
Charles Carlson, Chief Operations Officer and Secretary

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00102-of-00352.parquet"}]]